GNOM News and Press, Global X Genomics & Biotechnology ETF From 08/13/21

In any market’s upswing, there are always going to be people who make the case that “it’s different this time”, and historically, most of the time, that argument doesn’t hold up. I have never seen so many interesting and novel therapeutic opportuniti...

IvelinRadkov/iStock via Getty Images As the month ends for June and trading begins in July, investors can look back at the top-performing exchange traded funds for the month. Investors will see a mixed bag of names in the top-10 as major indices posted varying positive returns. One of the ETF...

From a consumer perspective, the consumer is actually now demanding a focus on environmental, social, governance factors. If public expectations for inflation do rise, that is going to be a change from years past. There’s going to be an opportunity to make medical progress ...

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...

Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare

In January 2020, only 0.24% of total medical claims in the U.S. were telemedicine-related. One year later, they totaled 7%. It took 15 years for e-commerce penetration to rise from less than 1% to over 7%. The pandemic helped telemedicine do it in one. Population-wide immunity to ...

This has been a long, long boom in the amount of money that's flowed into this sector, and I don't think I've ever seen anything like it in my own career. This has been VC money going into early-stage startups, it's been IPOs, it's been follow-on financing of already public companies....

Since U.S. Treasury bonds have fallen more than -20% in value, it looks like we might've seen a short-term bottom and an opportunity to profit in the bond market. Which sectors are performing well in the intermediate term, as well as those that are taking a breather in the short term....

One of my many favorite tools to use when analyzing the markets is a Relative Rotation Graph (or “RRG”). I’m going to focus on using RRG to explain what’s happening under the surface in the market today. You can put any benchmark in the middle, at the z...

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of thi...